Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
The European Medicines Agency’s CHMP upheld its negative opinion on Omeros’ narsoplimab application for TA-TMA after re-examination. Omeros also plans to end its compassionate-use program, while current patients will receive enough drug to complete treatment.
EMA's CHMP upheld its negative opinion on Omeros' narsoplimab marketing application following re-examination of its June 2026 decision. The application covers hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), which has no approved therapy in Europe. The FDA approved narsoplimab as Yarte